Drugs / Hymecromone
Hymecromone
also known as
H01 · 4-Methylumbelliferone · 4-MU · Cantabiline · DetoxPro · Heparmed · Heparvit · Himecromona · +3 more
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT06325696 | May 2025 → Dec 2027 expected | idiopathic pulmonary fibrosis | National Institute of Environmental Health Sciences (NIEHS) | Recruiting | No outcome recorded |
| Phase 2 | NCT05295680 | May 2023 → May 2027 expected | primary sclerosing cholangitis | Aparna Goel | Recruiting | No outcome recorded |
| Phase 2 | NCT05128929 | Apr 2022 → Sep 2023 | pulmonary hypertension | Stanford University | Completed | Missed primary |
| Phase 2 | NCT00225537 | Sep 2005 → Aug 2007 | chronic hepatitis B virus infection, chronic hepatitis C virus infection | MTmedical Institute of Health | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05386420 | May → Aug 2022 | COVID-19 | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02780752 Comparator | Dec 2020 → May 2021 | respiratory system disorder | Paul Bollyky | Completed | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hymecromone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05295680 ↗ |
| Known as | 4-Methylumbelliferone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00225537 ↗ |
| Known as | 4-MU | “whether hymecromone (4-methylumbelliferone [4-MU]), an oral drug approved in Europe for biliary spasm treatment that also inhibits HA in vitro and in animal models, could be...” PMID 35499083 ↗ May 2022 |
| Known as | Cantabiline | ChEMBL registry synonym — accepted as the source's own label CHEMBL12208 ↗ |
| Known as | DetoxPro | “Products containing 4-methylumbelliferone as their active substance have been available in the USA and Europe since 1990, as dietary supplements (under trade names Heparvit®,...” NCT00225537 ↗ |
| Known as | H01 | “Phase 2a, open-label, study to evaluate the safety, tolerability, and efficacy of H01 in adults with progressive interstitial lung disease.” NCT06325696 ↗1“Drug: Hymecromone (H01)” NCT05128929 ↗ |
| Known as | Heparmed | “Products containing 4-methylumbelliferone as their active substance have been available in the USA and Europe since 1990, as dietary supplements (under trade names Heparvit®,...” NCT00225537 ↗ |
| Known as | Heparvit | “Products containing 4-methylumbelliferone as their active substance have been available in the USA and Europe since 1990, as dietary supplements (under trade names Heparvit®,...” NCT00225537 ↗ |
| Known as | Himecromona | ChEMBL registry synonym — accepted as the source's own label CHEMBL12208 ↗ |
| Known as | LM-94 | ChEMBL registry synonym — accepted as the source's own label CHEMBL12208 ↗ |
| Known as | NSC-19026 | ChEMBL registry synonym — accepted as the source's own label CHEMBL12208 ↗ |
| Known as | NSC-9408 | ChEMBL registry synonym — accepted as the source's own label CHEMBL12208 ↗ |
| Action | Inhibit | “doses of hymecromone that effectively and safely lead to the inhibition of hyaluronan synthesis” NCT02780752 ↗ |
| Modality | Small molecule | “Their 7-hydroxycoumarin derivatives (4-methylumbelliferones)” NCT00225537 ↗ |
| Route | Oral | “Participants will be administered oral hymecromone 400mg po three times per day (1200 mg)” NCT02780752 ↗ |